Introduction: In recent decades, diabetes has contributed significantly to the burden of disease in developed and developing countries, due to the considerable prevalence and involvement of various age groups in the communities. Today, a variety of ways to manage and control the disease are used, one of which is the use of personal electronic health records. Recently there has been a remarkable upsurge in activity surrounding the adoption of personal electronic health records systems for patients and consumers. personal electronic health records systems are more than just static repositories for patient data; they combine data, knowledge, and software tools, which help patients to become active participants in their own care. The present study was conducted with the goal of Health Technology Assessment the impact of personal electronic health records in Patients with Diabetes. Methods and Analysis: Writing is based on PRISMA standards. This was a Health Technology Assessment study. It aimed to evaluate the technology of personal electronic health record. The scoping review was conducted to evaluate 8 dimensions (Health Problem and Current Use of the Technology, Description and technical characteristics of technology, Safety, Costs and economic evaluation, Ethical analysis, Organizational aspects, Patients and Social aspects, Legal aspects) of Personal electronic health record. This study was based on answering questions which were developed based on Health Diagnostics Technology Assessment Documents Framework and Health Technology Assessment (HTA) Core Model 3.0. A systematic review was conducted to evaluate the Clinical Effectiveness dimension of personal electronic health record in controlling diabetes. In order to gather evidences, Ovid databases, Cochrane Library, PubMed, CRD, Trip database and EMBASE, and Randomized Controlled Trial Registries, such as the Clinical Trial and Trial Registry, were searched using specific keywords and strategies. Articles are evaluated on the basis of the quality criteria of JADAD. The data is analyzed by the STATA software. Dissemination: The results of the study will be published in a peer-reviewed journal and presented at relevant conferences. Policy makers and healthcare decision-makers can use these results.
INTRODUCTION
Diabetes is a metabolic disorder that leads to absent the ability of the body to produce insulin or make the body to resistance against insulin; so, the produced insulin may not do its normal function, and finally, the blood glucose will in-global prevalence of diabetes reached to 382 million people in 2013. It is predicted that in 2035, it will reach about 592 million people (5) . In Iran, the number of individuals who were infected with this disease was 9.9% in 2013; according to predictions, it will reach to 10.1% in 2035 (6) . Nowadays, diabetes is epidemic in the world; the world's prevalence of diabetes increases by about 6% annually. Considering the increased prevalence of diabetes in the world, the treatment, control, and acute complications of diabetes require considerable expenditure by both patients and community health system. In a report which was published in 2001 by World Health Organization (WHO), in which the global burden of diseases was calculated, diabetes ranked 20 th in years lived with disability; in other words, 1.4% Years lost due to disability (YLD) was associated with this disease (7) .
The economic and physical consequences of diabetes are significant; it increases mortality and causes a lot of economic burdens (8) . However, the negative consequences of diabetes may be prevented (9) . The effective care and disease management are the only available solutions. The management of diabetes is complex and requires basic healthcare, coordinated care, nutritionist and endocrine experts' cooperation, etc. The patient education including proper lifestyle, healthy nutrition, having physical activity, and appropriate use of medications therapy is necessary to facilitate controlling blood glucose levels (10) . However, the increased number of people with diabetes, low numbers of primary care providers, and increasing healthcare costs have made it harder to take care of diabetic patients. In 2001, the National Academy of Medicine presented a solution to this problem which was known as improving communication between patients with chronic disease and self-care (11) .
The improved knowledge and performance of patients with diabetes mean improved metabolic situation control and performing proper self-care behaviors (12) . Therefore, the patients with diabetes will take care of him/herself well if he/she will be aware of his/her illness and treatment, tests, drugs, medical recommendations, follow-up visits, and blood glucose monitoring blood glucose levels. Indeed, the patients need conditions through which they may participate more in making decisions about their health status.To achieve this, the electronic personal health record (ePHR) is one of the appropriate tools which also empowers patients (13, 14) . The concept of ePHR has existed from the past and is not new. In the past, the patients hold their health information in paper form. Archer et al. (2011) reported that among 47% of patients who keep their health records, 87% stated that they keep them in paper form.Nowadays, the ePHR maintains the health and medical information of people in electronic form and they are available at anytime (15) . The ePHR is an electronic software in which people access and manage their medical information. Hence, people may access to this confidential information in a secure medium (16) .
This study aims to evaluate the technology of ePHR in patients with diabetes compared with those who only received routine services and have not used ePHR. It can helped policy-makers in entry, design, and how to use it.
In dictionary of International Bureau of Health Technology Assessment (HTAi), this field is defined as HTA is a systematic evaluation of clinical effectiveness, cost-effectiveness, or social and ethical effects of health technology on patient's life and healthcare system. This process specifies that whether the desired health technology should be used (17) . If so, how should it be used and which patients will benefit most from it? The evaluations are different, but it mostly focuses on cost and impact of technology on population or society.
According to this definition, the HTA studies address various dimensions of health technologies impacts; these dimensions may be divided into nine general domains including (health problem and current use of the technology, description and technical characteristics of technology, safety, clinical effectiveness, costs and economic evaluation, ethical analysis, organizational aspects, patients and social aspects, and legal aspects) The examination of these technology dimensions effects and their related results may influence policy-maker and decision-making.The HTA Core Model is a methodological framework for collaborative production and sharing of HTA information. The HTA Core Model is a registered trademark. According to HTA Core Model 3.0, the technology dimensions study in HTA includes some elements; questions should be answered in each element (18) .
METHODOLOGY
This was a HTA study. It aimed to evaluate the technology of ePHR. The scoping review was conducted to evaluate 8 dimensions (health problem and current use of the technology, description and technical characteristics of technology, safety, clinical effectiveness, costs and economic analysis, ethical issue, organizational aspects, patients and social aspects, and legal aspects) of ePHR. This study was based on answering questions which were developed based on Health Diagnostics Technology Assessment Documents Framework and HTA Core Model 3.0 (18) . A systematic review was conducted to evaluate the clinical effectiveness dimension of ePHRin controlling diabetes.
Questions
Databases including Cochrane library, PubMed, Center for Review and Dissemination(CRD), Trip database, and EM-BASE, randomized controlled trial (RCT) studies register databases (such as Clinical Trial and Trial Registry) were searched bykeywords as follow: personal health record, personal medical records, ePHR, diabetes mellitus, and records. The search was performed without any time and language limitation.The final articles were collected for systematic review based on the process of selecting specific resources; their quality was evaluated based on Critical Appraisal Skills Program (CASP) critical evaluation checklist which is designed for RCT studies. The structured questioning components (PICOD) at population, intervention, comparison, outcome, and design levels are as follows Table 1 and 2 both here . 
Examined dimension

Questions Answers
Selection of studies
The phase of searching and reviewing quality of articles will be done by two individuals independently. In the case of disagreement, the judgment was made by the third person. After completing the search, all found articles were entered into EndNote software, and the duplicates items will be deleted.Then, the titles and abstracts of articles will be reviewed by two people based on inclusion and exclusion criteria. In the case of unclear title and abstract, the full text was extracted. Also, articles' references will be reviewed and the related studies will be searched.The inclusion and exclusion criteria in the first (based on title and abstract) and second (based on full text) stages are as follows:
Inclusion and exclusion criteria of study • Population:
Items found
Query Search
The studies that have survey the other diseases more than diabetes will be excluted.
• Intervention:
The studies which have examined PHR will be excluded from.
The studies which have not studied target comparison group will be excluded.
The studies which have considered unrelated impact will be excluded from the study.
• Design:
Other types of studies other than related studies will be excluded.
Data Extraction
The data extraction checklist will be designed based on articles data. To ensure all authors who participate in study will obtain comparable data, the data of some articles will be entered in the pilot checklist. After modifying it, the final checklist will be designed and articles data will be extracted according to designed checklist.The checklist includes several parts as follow: the first part consist of main data of article such as title, corresponding author name, year of study, year of publication, place where the study was conducted, date on which the study began and ended, age of patients, and conflict of interests; the next parts includes items that are related to population and outcome of study. The selected studies will be divided into two groups, and each of them will be assigned to two colleagues for data extraction; each of them will independently extract the data from articles. After completing data extraction checklist, each of colleagues examine other colleague's data extraction checklist.
Evaluation of Bias Risk in Articles which are Entered into Meta-Analysis
If all studies will be RCT, the Cochrane Collaboration's Risk Bias (RoB) tool will be used. The bias risk in studies may be assessed using Cochrane Collaboration tool. We will use GRADE template making software to facilitate the presentation of findings of this evaluation. This assessment includes selection bias, relationship bias, performance bias, and biases in the identification, the report, and other bias sources including intervention compatibility, validity, and reliability of studies.
Analysis and Aggregation of Data
After a systematic search, if meta-analysis is possible, the selected studies will be entered into Rev Man and Stata software and based on a fixed or randomized model (the fixation model will be used in this study), the mean difference and confidence interval will be calculated.
Heterogeneity Assessment
The I2 and Chi-squared tests will be used to examine the heterogeneity of studies. In this method, according to values of I2 index, the heterogeneity level is presented as follows: low heterogeneity (25%-50%), medium heterogeneity (50%-75%), and high heterogeneity (more than 75%). If the numerical value of this index will be zero, it indicate that the results are homogeneous and if the score will be higher, it suggest that the results are heterogeneous. If the heterogeneity in results of various studies will be confirmed, the analysis will be conducted in subgroup analysis. Indded, the studies will be grouped based on probabilistic factors causing heterogeneity, and separate statistical analysis will be performed in each group. In the case of meta-analysis, the Forest Plot and Funnel Plot will be drawn.
Missing Items
Some articles will be excluded due to various reasons such as inaccessibility of full text. The data of missing items will not be considered (for primary or secondary outcomes) and will not affect results of this study.
Sensitivity Analysis
If necessary, the sensitivity analysis will be performed by re-running analyses without using studies that have high bias risk.
Evaluation of Quality of Studies
The JADAD criterion will be used to evaluate the quality of clinical trials studies. This checklist includes three main items including randomization, blindness, and description of results; the standard score for first and second items is 2 and for the third item is 1. Also, the expert views will be used to check the quality of articles. Among the factors which are considered for the evaluation of the quality of articles are validity of results, method of assigning participants to intervention and control groups, checking that the results are achievable, the external validity of results, etc.
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